These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3103494)

  • 21. [Therapy of ventricular tachyarrhythmia with disopyramid phosphate].
    Steinbrunn W; Mattmann H; Enrico JF; Engel U
    Schweiz Med Wochenschr; 1980 Jun; 110(24):953-7. PubMed ID: 7414314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intravenously disopyramide phosphate administration for treatment of arrhythmias].
    Aquaro G; Belli R; Pavia M; Rey L; Ravera A; Possavino G; Idone P
    G Ital Cardiol; 1982; 12(7):509-19. PubMed ID: 7169147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of intravenous disopyramide in the treatment of symptomatic refractory ventricular arrhythmia].
    Leone A
    Minerva Cardioangiol; 1984 Mar; 32(3):151-6. PubMed ID: 6728204
    [No Abstract]   [Full Text] [Related]  

  • 24. [Anti-arrhythmic effect of oral propafenone. Apropos of 70 cases].
    Coumel P; Leclercq JF; Assayag P; Maisonblanche P; Cauchemez B
    Arch Mal Coeur Vaiss; 1984 Nov; 77(12):1370-82. PubMed ID: 6439161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical studies of Norpace (Part II).
    Vismara L
    Angiology; 1975 Jan; 26(1 Pt 2):132-6. PubMed ID: 1090213
    [No Abstract]   [Full Text] [Related]  

  • 26. [Preventive disopyramide in patients with ventricular arrhythmias detected by exercise].
    Cardonne A; Pérez-Medina T; García-Barreto D
    Arch Inst Cardiol Mex; 1976; 46(1):69-73. PubMed ID: 779692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical studies of the antiarrhythmic efficacy of disopyramide phosphate (Norpace) (author's transl)].
    Smith WS
    Herz; 1978 Dec; 63(36):399-406. PubMed ID: 95482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical studies of Norpace (Part V).
    Cook WR
    Angiology; 1975 Jan; 26(1 Pt 2):140-1. PubMed ID: 1115401
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacodynamics and pharmacokinetics of disopyramide phosphate].
    Ol'binskaia LI; Tiukavkina NA; Kuz'mina MM; Beloborodov VL; Klimov AV
    Farmakol Toksikol; 1985; 48(4):73-8. PubMed ID: 3930285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Worsening of arrhythmias during pharmacological treatment.
    Furlanello F; Gramegna L; Dal Forno P; Vergara G; Bettini R; Inama G; Disertori M
    G Ital Cardiol; 1984 Oct; 14(10):798-803. PubMed ID: 6440827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disopyramide-induced ventricular tachycardia.
    Lo KS; Gantz KB; Stetson PL; Lucchesi BR; Pitt B
    Arch Intern Med; 1980 Mar; 140(3):413-4. PubMed ID: 6153888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias.
    Ekelund LG; Nilsson E; Walldius G
    Eur J Clin Pharmacol; 1986; 29(6):673-7. PubMed ID: 3519236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic therapy in heart failure.
    Eckardt L; Haverkamp W; Breithardt G
    Heart Fail Monit; 2002; 2(4):110-9. PubMed ID: 12634885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antiarrhythmic effect of disopyramid retard versus propranolol retard in ventricular extrasystole].
    Fechter P; Nager F
    Schweiz Med Wochenschr; 1982 Dec; 112(51):1897-900. PubMed ID: 6187065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral antiarrhythmic agents for ventricular arrhythmias.
    Meissner MD; Nestico PF; Morganroth J
    Clin Ther; 1986; 8(6):595-604. PubMed ID: 3539346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative studies on the cardiodepressant effect of disopyramide, mexiletine and propafenon].
    Angermann C; Jahrmärker H
    Z Kardiol; 1983 Nov; 72(11):665-74. PubMed ID: 6659643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
    Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
    Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dilated myocardiopathies: the relationship between the degree of cardiac dysfunction and ventricular arrhythmias. A clinical follow-up].
    Abreu A; Pereira H; Catarino C; Branco L; Valério L; Nunes H; Gonçalves JM; Gracias R; Antunes AM
    Rev Port Cardiol; 1993 Jan; 12(1):8, 33-7. PubMed ID: 8517976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.